Welcome to our dedicated page for Vyne Therapeutics SEC filings (Ticker: VYNE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
VYNE Therapeutics Inc. filings document the regulatory record for a clinical-stage biopharmaceutical company developing BET inhibitor therapies for inflammatory and immune-mediated conditions. Form 8-K disclosures include quarterly results, clinical and regulatory updates for Repibresib gel and VYN202, and capital-structure information for VYNE common stock.
The filing record also covers stockholder meeting results, director and governance matters, material-event reports, registered security information, and Nasdaq continued-listing compliance disclosures, including minimum bid price notices and extension communications.
VYNE Therapeutics Inc. reported that a non-employee director received an annual stock option award on December 12, 2025, the date of the company’s annual meeting of stockholders. The filing shows the grant of 20,000 stock options to purchase VYNE common stock at an exercise price of $0.3756 per share. These options vest on December 12, 2026, conditioned on the director’s continuous service through that date, and are scheduled to expire on December 11, 2035. Following this transaction, the director is shown as beneficially owning 20,000 derivative securities, all held directly.
VYNE Therapeutics Inc. reported the results of its 2025 annual meeting of stockholders held on December 12, 2025, where all three proposals on the ballot were approved. Of the 33,286,422 shares outstanding as of the record date, 16,680,776 shares, or 50.1%, were present or represented by proxy, providing a bare majority quorum.
Stockholders elected Class I directors Elisabeth Sandoval Little and Steven Basta to serve until the 2028 annual meeting, with each nominee receiving more votes for than withheld, plus 11,377,870 broker non-votes. They also ratified the selection of Baker Tilly US, LLP as independent registered public accounting firm for the fiscal year ending December 31, 2024, by a vote of 15,296,776 for, 766,080 against, and 617,920 abstentions.
On an advisory basis, stockholders approved the compensation of the company’s named executive officers, with 4,566,359 votes for, 680,945 against, 55,602 abstentions, and 11,377,870 broker non-votes. Overall, the meeting confirmed the company’s board choices, auditor, and executive pay program.
VYNE Therapeutics reported Q3 results reflecting a clinical-stage pivot and tighter spending. Royalty revenues were $169 thousand, while operating expenses fell to $8.0 million from $13.2 million a year ago, yielding an operating loss of $7.8 million and a net loss of $7.3 million. For the nine months, net loss was $21.6 million.
Liquidity remained stable with $32.7 million in cash, cash equivalents and marketable securities as of September 30, 2025, no debt, and total assets of $36.1 million. Operating cash use was $29.4 million year‑to‑date; management believes existing resources fund operations for at least 12 months, and cost reductions are expected to extend runway into the first half of 2027.
Pipeline updates: the FDA imposed a partial clinical hold on VYN202 in April; dosing for females at two doses resumed in June, with a 12‑week dog toxicology study initiated to address male enrollment. VYNE terminated the Phase 1b psoriasis trial after unblinding seven subjects showed directional improvements and plans to advance VYN202 in other immune‑mediated diseases. The Phase 2b repibresib (VYN201) vitiligo study did not meet primary and key secondary endpoints; VYNE is seeking a partner. A strategic review, including potential partnerships or transactions, is ongoing.
VYNE Therapeutics Inc. furnished a press release announcing its financial results for the quarter ended September 30, 2025. The press release is provided as Exhibit 99.1 to an Item 2.02 Form 8-K and is incorporated by reference.
The Item 2.02 information and Exhibit 99.1 are being furnished, not filed, under the Exchange Act.
VYNE Therapeutics Inc. Chief Financial Officer Zeronda Tyler reported a Form 4 disclosing a non‑derivative disposition on 09/30/2025. The filing shows 3,420 shares of common stock were disposed of at a price of $0.335 per share. The filing explains these shares were withheld by the issuer to satisfy tax withholding obligations related to the vesting of restricted stock units. After the reported transaction, the reporting person beneficially owns 111,653 shares, held in a direct ownership form. The Form 4 is signed by an attorney‑in‑fact and contains no other transactions or derivative instruments.
VYNE Therapeutics Inc. reporting person David Domzalski, who serves as President and CEO and a Director, reported a transaction dated 09/30/2025. The filing shows 12,676 shares of common stock were disposed of under code F at a price of $0.335 per share; the form explains these shares were withheld by the issuer to satisfy tax withholding for vested restricted stock units. After the withholding, the reporting person beneficially owned 428,892 shares.
The Form 4 was signed by an attorney-in-fact on behalf of the reporting person on 10/02/2025. No derivative transactions are reported on this form and no other transactions or compensatory changes are disclosed.
Eventide Asset Management, LLC and two affiliated individuals filed an amendment on Schedule 13G disclosing beneficial ownership of 1,849,597 shares of VYNE Therapeutics common stock, representing 9.99% of the class based on 16,664,892 shares outstanding. The filing states these holdings reflect common stock issuable upon exercise of pre-funded warrants exercisable for up to 5,287,413 shares, but exercise is limited so the holder will not exceed 9.99%. The amendment explains the change was to disclose a different mix of security types and includes signatures dated August 14, 2025.
Cormorant Asset Management, LP and Bihua Chen report beneficial ownership of 1,370,938 shares of VYNE Therapeutics, representing 8.23% of the outstanding common stock. The reported position reflects shared voting and shared dispositive power only; the reporting persons state they have no sole voting or sole dispositive power over these shares.
The holding is reported as held by the Cormorant Funds, and the filing notes that Cormorant Global Healthcare Master Fund, LP has the right to receive dividends or sale proceeds for more than 5% of the shares. The percentage is calculated using 16,664,892 shares outstanding as reported by the issuer as of May 1, 2025. The reporting persons certify the shares are held in the ordinary course of business and not to influence control of the issuer.
VYNE Therapeutics furnished a press release reporting financial results for the quarter ended June 30, 2025; that press release is attached as Exhibit 99.1. The filing states the exhibit is being furnished and not "filed" for purposes of Section 18 of the Exchange Act. The report itself does not include the financial figures in this 8-K.
The registrant also disclosed that Christine Borowski, Ph.D. and Anthony Bruno resigned from the board effective immediately, each leaving their committee roles; the company stated the resignations were not due to any disagreement with the company or board and expressed thanks for their contributions.